FeesSafety
Pluang+

Halozyme shares fall on revenue growth concerns despite strong royalty gains and raised earnings forecast

19 Nov 2026, 20:23 WIB
Seeking Alpha
View Source
Bullish
Halozyme shares fall on revenue growth concerns despite strong royalty gains and raised earnings forecast

Halozyme Therapeutics shares dropped due to worries about slowing sequential revenue growth and a broader selloff in AI-related stocks. Despite this, the company reported a 44.5% year-over-year increase in royalty revenue to $341 million in Q3 and raised its 2026 non-GAAP diluted EPS guidance from $8.65-$9.00 to $8.75-$9.05. Halozyme's three drug delivery technologies and partnerships with major pharmaceutical firms contribute to its attractive risk/reward profile, making it a notable mid-cap biotech stock to watch.

Halozyme Therapeutics shares are down 2.91% on Pluang, trading at USD 93.01 as of Nov 20, 2026 01:41 WIB. The stock's market cap stands at $10.94 billion, reflecting ongoing investor caution despite the company's strong revenue growth and raised EPS guidance.

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App